The prevention of colitis by E prostanoid receptor 4 agonist through enhancement of epithelium survival and regeneration

Journal of Pharmacology and Experimental Therapeutics

Volumn 320, Issue 1, 2007, Pages 22-28

  Jiang, Guang Liang ^a   Nieves, Amelia ^a   Wha, Bin Im ^a   Old, David W ^a   Dinh, Danny T ^a   Wheeler, Larry ^a  

^a ALLERGAN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 [2 (3 HYDROXY 4 PHENYL BUT 1 ENYL) 6 OXO PIPERIDIN 1 YL] HEPTANOIC ACID METHYL ESTER; 7 [2 93 HYDROXY 4 PHENYL BUT 1 ENYL) 6 OXO PIPERIDIN 1 YL] HEPTANOIC ACID; [[3 [[3 HYDROXY 2 [3 HYDROXY 4 [3 (METHOXYMETHYL)PHENYL] 1 BUTENYL] 5 OXOCYCLOPENTYL]THIO]PROPYL]THIO] ACETIC ACID; AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; AGN 205203; AGN 205204; DEXTRAN; E PROSTANOID RECEPTOR 4; INDOMETACIN; NONSTEROID ANTIINFLAMMATORY AGENT; ONO AE1329; PIPERIDONE DERIVATIVE; PROSTAGLANDIN E RECEPTOR; PROSTANOID RECEPTOR; SODIUM SULFATE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CELL PROTECTION; COLITIS; COLON HEMORRHAGE; COLUMNAR EPITHELIUM; CONTROLLED STUDY; CYTOTOXICITY; DIARRHEA; DRUG ACTIVITY; DRUG EFFECT; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG STABILITY; DRUG STRUCTURE; ELIMINATION REACTION; EPITHELIUM; EPITHELIUM CELL; FEMALE; GOBLET CELL; HISTOLOGY; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN INTERACTION; TISSUE REGENERATION; WEIGHT REDUCTION;

ANIMALS; APOPTOSIS; CELL SURVIVAL; COLON; FEMALE; INFLAMMATORY BOWEL DISEASES; INTESTINAL MUCOSA; MICE; MICE, INBRED C57BL; PROLIFERATING CELL NUCLEAR ANTIGEN; RECEPTORS, PROSTAGLANDIN E; REGENERATION; SPLEEN;

EID: 33845889285     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.106.111146     Document Type: Article

References (36)

1. 35S binding, transferable to 5-HT2A and 5-HT2B, upon swapping intracellular regions. Br J Pharmacol 138:427-434.
2. Bernstein CN and Nabalamba A (2006) Hospitalization, surgery, and readmission rates of IBD in Canada: a population-based study. Am J Gastroenterol 101:110-118.
3. Colombel JF, Loftus EV Jr, Tremaine WJ, Egan LJ, Harmsen WS, Schleck CD, Zinsmeister AR, and Sandborn WJ (2004) The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. Gastroenterology 126:19-31.
4. Dignass AU (2001) Mechanisms and modulation of intestinal epithelial repair. Inflamm Bowel Dis 7:68-77.
5. Einerhand AW, Renes IB, Makkink MK, van der Sluis M, Buller HA, and Dekker J (2002) Role of mucins in inflammatory bowel disease: important lessons from experimental models. Eur J Gastroenterol Hepatol 14:757-765.
6. Fujino H and Regan JW (2006) EP(4) prostanoid receptor coupling to a pertussis toxin-sensitive inhibitory G protein. Mol Pharmacol 69:5-10.
7. Fujino H, Xu W, and Regan JW (2003) Prostaglandin E2 induced functional expression of early growth response factor-1 by EP4, but not EP2, prostanoid receptors via the phosphatidylinositol 3-kinase and extracellular signal-regulated kinases. J Biol Chem 278:12151-12156.
8. Goulet JL, Pace AJ, Key ML, Byrum RS, Nguyen M, Tilley SL, Morham SG, Langenbach R, Stock JL, McNeish JD, et al. (2004) E-prostanoid-3 receptors mediate the proinflammatory actions of prostaglandin E2 in acute cutaneous inflammation. J Immunol 173:1321-1326.
9. Hase S, Yokota A, Nakagiri A, and Takeuchi K (2003) Prostaglandin E2 aggravates gastric mucosal injury induced by histamine in rats through EP1 receptors. Life Sci 74:629-641.
10. Hata AN and Breyer RM (2004) Pharmacology and signaling of prostaglandin receptors: multiple roles in inflammation and immune modulation. Pharmacol Ther 103:147-166.
11. Hoshino T, Tsutsumi S, Tomisato W, Hwang HJ, Tsuchiya T, and Mizushima T (2003) Prostaglandin E2 protects gastric mucosal cells from apoptosis via EP2 and EP4 receptor activation. J Biol Chem 278:12752-12758.
12. Isaacs KL, Lewis JD, Sandborn WJ, Sands BE, and Targan SR (2005) State of the art: IBD therapy and clinical trials in IBD. Inflamm Bowel Dis 11:S3-S12.
13. Joseph RR, Yazer E, Hanakawa Y, and Stadnyk AW (2005) Prostaglandins and activation of AC/cAMP prevents anoikis in IEC-18. Apoptosis 10:1221-1233.
14. Kabashima K, Saji T, Murata T, Nagamachi M, Matsuoka T, Segi E, Tsuboi K, Sugimoto Y, Kobayashi T, Miyachi Y, et al. (2002) The prostaglandin receptor EP4 suppresses colitis, mucosal damage and CD4 cell activation in the gut. J Clin Investig 109:883-893.
15. Kitajima S, Takuma S, and Morimoto M (2000) Histological analysis of murine colitis induced by dextran sulfate sodium of different molecular weights. Exp Anim 49:9-15.
16. Krieglstein CF, Cerwinka WH, Sprague AG, Laroux FS, Grisham MB, Koteliansky VE, Senninger N, Granger DN, and de Fougerolles AR (2002) Collagen-binding integrin alpha1beta1 regulates intestinal inflammation in experimental colitis. J Clin Investig 110:1773-1782.
17. Lim WC and Hanauer SB (2004) Emerging biologic therapies in inflammatory bowel disease. Rev Gastroenterol Disord 4:66-85.
18. Loftus EV Jr (2004) Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology 126:1504-1517.
19. Loftus EV Jr, Kane SV, and Bjorkman D (2004) Systematic review: short-term adverse effects of 5-aminosalicylic acid agents in the treatment of ulcerative colitis. Aliment Pharmacol Ther 19:179-189.
20. Meyer AM, Ramzan NN, Heigh RI, and Leighton JA (2006) Relapse of inflammatory bowel disease associated with use of nonsteroidal anti-inflammatory drugs. Dig Dis Sci 51:168-172.
21. Morteau O, Morham SG, Sellon R, Dieleman LA, Langenbach R, Smithies O, and Sartor RB (2000) Impaired mucosal defense to acute colonic injury in mice lacking cyclooxygenase-1 or cyclooxygenase-2. J Clin Investig 105:469-478.
22. Nitta M, Hirata I, Toshina K, Murano M, Maemura K, Hamamoto N, Sasaki S, Yamauchi H, and Katsu K (2002) Expression of the EP4 prostaglandin E2 receptor subtype with rat dextran sodium sulphate colitis: colitis suppression by a selective agonist, ONO-AE1-329. Scand J Immunol 56:66-75.
23. Northey A, Denis D, Cirino M, Metters KM, and Nantel F (2000) Cellular distribution of prostanoid EP receptors mRNA in the rat gastrointestinal tract. Prostaglandins Other Lipid Mediat 62:145-156.
24. Ohnishi A, Shimamoto C, Katsu K, Ito S, Imai Y, and Nakahari T (2001) EP1 and EP4 receptors mediate exocytosis evoked by prostaglandin E(2) in guinea-pig antral mucous cells. Exp Physiol 86:451-460.
25. Old DW and Dinh TD (2004) inventors, Allergan, Inc., assignee. Piperidinyl prostaglandin E analogs. U.S. patent 6,747,037 B1. 2004 Jun 8.
26. Redlak MJ, Power JJ, and Miller TA (2005) Role of mitochondria in aspirin-induced apoptosis in human gastric epithelial cells. Am J Physiol 289:G731-G738.
27. Shaoul R, Okada Y, Cutz E, and Marcon MA (2004) Colonic expression of MUC2, MUC5AC, and TFF1 in inflammatory bowel disease in children. J Pediatr Gastroenterol Nutr 38:488-493.
28. Shichijo K, Makiyama K, Wen CY, Matsuu M, Nakayama T, Nakashima M, Ihara M, and Sekine I (2005) Antibody to eosinophil cationic protein suppresses dextran sulfate sodium-induced colitis in rats. World J Gastroenterol 11:4505-4510.
29. Shimamoto C, Fujiwara S, Kato M, Ito S, Katsu K, Mori H, and Nakahari T (2005) Inhibition of ACh-stimulated exocytosis by NSAIDs in guinea pig antral mucous cells: autocrine regulation of mucin secretion by PGE2. Am J Physiol 288:G39-G47.
30. Shoji Y, Takahashi M, Kitamura T, Watanabe K, Kawamori T, Maruyama T, Sugimoto Y, Negishi M, Narumiya S, Sugimura T, et al. (2004) Downregulation of prostaglandin E receptor subtype EP3 during colon cancer development. Gut 53:1151-1158.
31. Stein J, Ries J, and Barrett KE (1998) Disruption of intestinal barrier function associated with experimental colitis: possible role of mast cells. Am J Physiol 274:G203-G209.
32. Takafuji V, Cosme R, Lublin D, Lynch K, and Roche JK (2000) Prostanoid receptors in intestinal epithelium: selective expression, function, and change with inflammation. Prostaglandins Leukot Essent Fatty Acids 63:223-235.
33. Takeuchi K, Ueki S, and Okabe S (1986) Importance of gastric motility in the pathogenesis of indomethacin-induced gastric lesions in rats. Dig Dis Sci 31:1114-1122.
34. Thiefin G and Beaugerie L (2005) Toxic effects of nonsteroidal antiinflammatory drugs on the small bowel, colon, and rectum. Joint Bone Spine 72:286-294.
35. Wiercinska-Drapalo A, Flisiak R, and Prokopowicz D (1999) Effects of ulcerative colitis activity on plasma and mucosal prostaglandin E2 concentration. Prostaglandins Other Lipid Mediat 58:159-165.
36. Yu Y, Sitaraman S, and Gewirtz AT (2004) Intestinal epithelial cell regulation of mucosal inflammation. Immunol Res 29:55-68.